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Abstract
Background: Recent evidence has demonstrated that cardiac progenitor cells play an essential role in the
induction of angiomyogenesis in infarcted myocardium. We and others have shown that engraftment of c-kit+
cardiac stem cells (CSCs) into infarcted hearts led to myocardium regeneration and neovascularization, which was
associated with an improvement of ventricular function. The purpose of this study is aimed at investigating the
functional role of transcription factor (TF) Oct3/4 in facilitating CSCs to promote myocardium regeneration and
preserve cardiac performance in the post-MI heart.
Methods: c-kit+ CSCs were isolated from adult hearts and re-introduced into the infarcted myocardium in which
the mouse MI model was created by permanent ligation of the left anterior descending artery (LAD). The Oct3/4 of
CSCs was inhibited by transfection of Oct3/4 siRNA, and transfection of CSCs with control siRNA serves as control
groups. Myocardial functions were evaluated by echocardiographic measurement. Histological analysis was
employed to assess newly formed cardiogenesis, neovascularization, and cell proliferations. Terminal
deoxynucleotidyltransferase (TdT) nick-end labeling (TUNEL) was carried out to assess apoptotic cardiomyocytes.
Real time polymerase chain reaction and Western blot were carried out to evaluate the level of Oct 3/4 in CSCs.
Results: Two weeks after engraftment, CSCs increased ventricular functional recovery as shown by a serial
echocardiographic measurement, which is concomitant with the suppression of cardiac hypertrophy and
attenuation of myocardial interstitial fibrosis. Suppression of Oct 3/4 of CSCs abrogated functional improvements
and mitigated the hypertrophic response and cardiac remodeling. Transplantation of c-kit+ CSCs into MI hearts
promoted cardiac regeneration and neovascularization, which were abolished with the knockdown of Oct3/4.
Additionally, suppression of Oct3/4 abrogated myocyte proliferation in the CSC-engrafted myocardium.
Conclusion: Our results indicate that CSCs-derived cardiac regeneration improves the restoration of cardiac
function and is mediated through Oct 3/4.
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Background
Cardiovascular disease (CVD) is the leading cause of
deaths worldwide, with myocardial infarction (MI) being
associated with significant morbidity and mortality. Des-
pite significant improvements in medical prevention and
treatment, the incidence and prevalence of MI-induced
heart failure have been increasing steadily [1]. MI often
leads to heart failure because of a loss of viable heart
muscle and impaired left ventricular function. The lack
of regenerative potential of cardiac tissue and insuffi-
cient therapeutic options lead to poor prognosis for pa-
tients with CVD. The myocardium has long been
considered as a terminally differentiated organ because
adult cardiomyocytes exhibit little proliferative activity
relative to the fetal stage, and until recently it was seen
as lacking in regenerative capacity [2, 3]. The adult heart
has now been recognized to harbor distinct populations
of cardiac progenitors [4], which have the potential to
differentiate into cardiomyocytes, endothelia, and vascu-
lar smooth muscle cells. Furthermore, several studies
have shown that these cardiac progenitor cells are cap-
able of differentiating into cardiac tissue and improving
cardiac function after myocardial injury. Exponential ad-
vances in stem cell and regenerative biology are begin-
ning to foster a transition towards therapeutic goals for
cardiac regenerative medicine [5–7]. Various studies
have identified myocardial precursor cells in the postna-
tal hearts using several different cell surface markers [4, 8,
9]. Many reports have demonstrated that the myocar-
dium harbors a stem cell-like myocyte population with
the properties of self-renewal, replication, and clono-
genicity [10]. Furthermore, cardiac progenitor cells have
been found to have the capacity of differentiating into
cardiac tissue and improving cardiac function after a
myocardial injury. These new findings led to a novel un-
derstanding of both normal and pathologic cardiac de-
velopments and homeostasis, and foster a transition
towards therapeutic goals for cardiac regenerative medi-
cine. However, poor cell viability, proliferation, and inef-
ficient differentiation following transplantation have
limited the reparative capacity of these cells in vivo.
Thus, molecular intervention strategies to enhance car-
diac stem cell (CSC) proliferation and survival hold dra-
matic consequences for enhancing myogenesis and will
empower a therapeutically relevant implementation of
myocardial regeneration. Studies have reported that gen-
etically modified stem cells could repair the infarcted
myocardium, prevent remodeling, and nearly normalize
cardiac performance [11, 12].
POU family homeodomain transcription factor Oct3/
4, also known as POUF51, is expressed in the early stage
of embryonic development and plays a pivotal role in
regulating lineage progression in embryonic stem cells
(ESCs) [13]. Oct3/4 (also termed Oct3, Oct 3/4, or
POU5F1) is critical for mammalian embryonic develop-
ment and for ESC pluripotency [14, 15]. Recent evidence
demonstrates that Oct3/4 serves as a transcriptional or-
ganizer to modulate pluripotency and differentiation
[13]. Together with Sox2 and Nanog, Oct3/4 works as a
gatekeeper of pluripotency in ESCs by maintaining its
endogenous expression level. In the revolutionary study
conducted by the Yamanaka group, Oct3/4 was found to
be one of four transcriptional factors that can reprogram
differentiated cells into induced pluripotent stem cells
(iPSCs) [16, 17]. It also can direct the ESC toward a
mesodermal cardiogenic fate. Oct3/4 and Sox17 have
been reported to cooperatively drive human pluripotent
stem cells into cardiac progenitors [18]. Li et al. [19]
demonstrated that formation of Oct3/4–Wnt ternary
complexes contributes to the activation of cardiac
lineage-related genes through regulating the cardiac
lineage factor Mesp1. This evidence indicates that Oct3/
4 of stem cells can direct cell pluripotency as well as de-
termining the cell lineage commitment, which is likely
dependent on the cell type and experimental models.
However, the genetic and epigenetic mechanisms under-
lying the dual function of Oct3/4, in maintaining pluri-
potency, or inducing lineage commitment in cardiac
progenitor cell-derived regeneration, have yet to be thor-
oughly investigated. In this present study, we aimed to
assess the crucial role of Oct3/4 in the modulation of
CSC-derived cardiac repair and neovascularization in
cell-engrafted MI hearts. Our results presented here
demonstrate that Oct3/4 plays a pivotal role in directing




All animal procedures were carried out in accordance
with the guidelines approved by the Institutional Animal
Care and Use Committee of Roger Williams Medical
Center. CD-1 mice were purchased from Charles River
Laboratories (Wilmington, MA, USA) and housed at
Animal Care Facility of Roger Williams Medical Center
on a 12-hour light/dark cycle with free access to water
and standard mouse food.
c-kit+ CSC isolation, establishment of stable GFP-c-kit+
CSCs, and small interfering RNA transfection
c-kit+ CSCs were isolated as described previously [20, 21].
Ventricular tissues from 3-month-old male CD-1 mice
were minced into small pieces and subjected to enzymatic
dissociation with a mixture of 0.2 % trypsin and
0.1 % collagenase IV (Worthington Biochemical Corp.,
www.worthington-biochem.com) in phosphate-buffered
saline (PBS) three times for 5 minutes at 37 °C. After
treatment, the remaining tissue fragments were cultured
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as explants in explant medium (Iscove’s modified
Dulbecco’s medium (IMDM) with 10 % fetal calf serum
(FBS) containing 100 U/ml penicillin G, 100 μg/ml
streptomycin, 2 mmol/l L-glutamine, and 0.1 mmol/l 2-
mercaptoethanol) at 37 °C under normal tissue culture
conditions. Three weeks after cell inoculation, small
phase-bright cells migrating above the fibroblast layer
were formed from adherent explants. In order to avoid
damaging the integrity of the surface antigen of cells, these
phase-bright cells were collected simply by washing with
D-Hanks. The cell suspension was filtered through a
40 μm cell strainer (BD Falcon, www.bdbiosciences.com),
and cell numbers were counted. The selected CSCs
were cultured and maintained in complete media contain-
ing DMEM (Dulbecco's Modified Eagle's medium)/F12,
10 % fetal calf serum, 200 mML-glutamine, 55 nM
β-mercaptoethanol, and 1 % MEM (Minimum Essential
Medium) nonessential amino acids (Invitrogen Corpor-
ation ). To enrich the c-kit+ CSCs, c-kit+ cells were isolated
by magnetic cell sorting with CD117 magnetic beads (Milte-
nyi Biotec Inc., Auburn, CA, USA) as instructed by the
manufacturer’s protocols. To track the fate of transplanted
CSCs in the infarcted hearts, a stable c-kit+ CSC line
expressing green fluorescent protein (GFP) was established.
Freshly isolated c-kit+ CSCs were transfected with the linear-
ized pEGFP using lipofectamine™ 2000 (Invitrogen Corpor-
ation, Carlsbad, CA, USA) and maintained in the presence
of G418 (500 μg/l) for 2 weeks. The transfected GFP-c-kit+
CSC-positive colonies were formed, picked up under fluor-
escent microscopy, and expanded for subcultures in the
medium already described. To prevent the effects of
multiple passages on CSCs, CSCs at passage 4 were used
in this study. The method of small interfering RNA
(siRNA) transfection was conducted using the lipofecta-
mine™ 2000 transfection kit (Thermo Fisher, Waltham,
MA, USA) according to the manufacturer’s instructions.
Oct3/4 siRNA (mouse) was used in these studies, which
consist of a pool of three different siRNA duplexes (Santa
Cruz Biotech, Santa Cruz, CA, USA). The sequences of
Oct3/4 siRNA 1 duplexes are as follows: Oct3/4 siRNA
sc-36124A, sense 5′-GAAGGAUGUGGUUCGAGUAtt-
3′ and antisense 5′-UACUCGAACCACAUCCUUCtt-3′;
sc-36124B, sense 5′-GCUCUCCCAUGCAUUCAAAtt-
3′ and antisense 5′-UUUGAAUGCAUGGGAGAGCtt-
3′; sc-36124C, sense 5′-CCUUCAGGAGAUAUG
CAAAtt-3′ and antisense 5′-UUUGCAUAUCUCCU
GAAGGtt–3′. The negative control (scrambled) siRNA
and Oct3/4 siRNA were mixed with Lipofectamine™
2000 at a final concentration of 500 nmol/L siRNA in
medium, respectively. Forty-eight hours after siRNA
transfection, in vivo allogeneic c-kit+ CSC transplant-
ation was performed during the left anterior descend-
ing coronary artery (LAD) ligation operation in MI
mice.
Myocardial infarction
Adult mice were randomized into four groups: 1) sham
group, sham-operated mice; 2) MI-PBS group, mice with
MI receiving PBS injection; 3) MI-CSCs-Oct3/4(+) group,
mice with MI receiving control siRNA-treated CSC trans-
plantation; 4) and MI-CSCs-Oct3/4(−) group, mice with
MI receiving Oct3/4 siRNA-treated c-kit+ CSC transplant-
ation. LAD ligation was performed on all groups except on
the sham group to induce MI following thoracotomy, as
described previously [21]. Briefly, mice were anesthetized
with pentobarbital sodium (50 mg/kg) intraperitoneally,
intubated, and then ventilated with positive pressure using
a ventilator (Harvard Apparatus Inspira, Holliston, MA,
USA). Additional doses of pentobarbital were given as
needed during the procedure to maintain an anesthetized
state. After a left-sided thoracotomy, the hearts were ex-
posed and the LADs were occluded by a permanent
ligation using a 7–0 suture (Ethicon, Norderstedt,
Germany). Mice in the sham group were anesthetized and
underwent thoracotomy without coronary ligation.
In vivo allogeneic c-kit+ CSC transplantation
Upon completion of LAD ligation, a total of 5 × 105 GFP-
labeled c-kit+ CSCs were suspended in 10 μl PBS and
directly injected into five sites in the border zone of the
infarcted left ventricle. Mice in the MI-CSCs-Oct3/4(+)
group received control siRNA-treated c-Kit+ CSCs, while
MI-CSCs-Oct3/4(−) mice received Oct3/4 siRNA-treated
c-Kit+ CSCs. The MI-PBS group received PBS-only injec-
tions. Following CSC/PBS injections, the chest was closed
in a layered fashion, and air was evacuated to prevent
pneumothorax. Myocardial functions were assessed by
echocardiographic measurement. At the end of experiment,
5-ethynyl-2′-deoxyuridine (EdU, 50 mg/kg) was intraperito-
neally injected into animals 24 hours prior to euthanization
for assessment of cell proliferation in vivo.
Echocardiography
Two weeks after LAD ligation and CSC engraftment, left
ventricular (LV) function was evaluated by transthoracic
echocardiography using an Acuson Sequoia C512 sys-
tem (Siemens Healthcare, Malvern, PA, USA) equipped with
a 15 L8 linear array transducer. Mice were anesthetized with
1.5 % isoflurane mixed with oxygen via a nose cone, and
then placed in supine position on a heating pad. The precor-
dial region was covered with prewarmed ultrasound trans-
mission gel (Aquasonic; Parker Laboratory, Fairfield, NJ,
USA) after removal of hair. Two-dimensional short-axis
images were obtained and recorded at the level of the
mid-papillary muscle in both B-mode and M-mode. The
signal depth was set at 25 mm. Three to six consecutive
cardiac cycles were measured from M-mode tracings with
accompanying software. LV internal dimension in
diastole (LVID;d), LVID in systole (LVID;s), LV ejection
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fraction (LVEF), and LV fractional shortening (LVFS)
were calculated as indexes of LV function.
Immunohistochemistry
Animals were sacrificed after echocardiographic mea-
surements, and tissues were harvested for immunocyto-
chemistry and histological analyses. Hearts were isolated
and fixed in 4 % buffered formalin, then dehydrated and
embedded in paraffin. Heart sections were cut, mounted,
deparaffinized in xylene, and rehydrated through an
ethanol series. Paraffin-embedded tissues were analyzed
for fibrosis, pathological hypertrophy, and angiogenesis.
Interstitial collagen deposition was assessed by picro-
sirius red staining. Tissue sections were stained with
picro-sirius red solution for 1 hour at room temperature
following 8 minutes of hematoxylin staining. After dehy-
drating the slides, collagen content was determined from
five randomly selected regions from each tissue section
at 40× magnification using an Olympus BX51 micro-
scope (Olympus, Center Valley, PA, USA). For immuno-
fluorescence staining, antigen retrieval was performed
on deparaffinized tissue sections by boiling slides in cit-
rate buffer at 100 °C for 1 hour. Slides then were blocked
in 1 % bovine serum for 1 hour at room temperature
followed by overnight incubation with primary anti-
bodies at 4 °C. The following primary antibodies were
used in this study: newly formed c-kit+ CSC-derived
myocytes were identified with polyclonal GFP and cost-
ained with α-sarcomeric actinin (both Life Technologies,
Carlsbad, CA, USA), microvessel densities were exam-
ined by anti-α-smooth muscle actin (α-SMA) monoclo-
nal antibody (Sigma, St. Louis, MO, USA), CD31 (anti-
PECAM-1; Millipore, Billerica, MA, USA) was used to
identify capillaries in myocardium, polyclonal Ki67 for
the cycling myocytes (Novocastra, Milton Keynes, UK)
was used to detect the cycling cells, and phosphorylated
histone 3 (PH3; Abcam, Cambridge, MA, USA) was
used to detect mitosis. After washing in PBS, signals
were then visualized by incubating at room temperature
for 1 hour with secondary antibodies of Alexa Fluor 488
or 555-conjugated goat anti-mouse, anti-rabbit, or anti-
rat antibody (Life Technologies) for 1 hour at room
temperature. 4,6-Diamidino-2-phenylindole (DAPI; Life
Technologies) was used to identify nuclei. Cross-
sectional cell area measurements were obtained in cross-
sectioned left ventricles and were measured by overnight
staining with wheat germ agglutinin (WGA, fluorescein
isothiocyanate-conjugated; Life Technologies) on depar-
affinized slides at 4 °C. Confocal fluorescent imagining
was performed using a Carl Zeiss LSM 700 laser scan-
ning microscope equipped with intuitive ZEN 2009 soft-
ware (Carl Zeiss Microscopy, Jena, Germany). Five to 10
randomly selected high-power fields were selected for
quantifications using ImageJ software (version 1.40 g;
NIH, http://rsb.info.nih.gov/ij/). A minimum of 200
myocytes from five different animals was quantified for
each experimental group. Global heart architecture was
determined by staining with a Trichrome Stain (Masson)
Kit (Sigma-Aldrich, St. Louis, MO, USA) following the
manufacturer’s instructions. The infarction size was
determined and expressed as the ratio of scar length to
LV circumferences of the endocardium and epicardium.
Terminal deoxynucleotidyltransferase nick-end labeling
Terminal deoxynucleotidyltransferase nick-end labeling
(TUNEL) was carried out using a TACS 2-TdT-DAB In
Situ Apoptosis Detection Kit (Trevigen Inc., Gaithers-
burg, MD, USA) following the manufacturer’s instruc-
tions, using an 1-hour labeling reaction in the presence
of cobalt. To verify that apoptosis occurred in the myo-
cytes, immunohistochemical staining of α-sarcomeric
actin was carried out with an α-sarcomeric actin anti-
body (α-actin, monoclonal, 1:100 dilution; Sigma) at 4 °C
overnight. For each section, the number of TUNEL-
positive myocyte nuclei was counted in five randomly
selected regions. The index of apoptosis was then
determined.
Real-time polymerase chain reaction
Total RNA was extracted from CSCs from different
groups with Trizol reagent (Life Technologies, Grand Is-
land, NY, USA). cDNA was synthesized from 5 μg total
RNA. The reverse-transcribed cDNA (5 μl) was ampli-
fied to a final volume of 50 μl by PCR under standard
conditions. Real-time PCR experiments were performed
on a master cycler realplex4 (Eppendorf North America,
Hauppauge, NY, USA) system using qPCR Kit master
mix (Kapabiosystems, Boston, MA, USA) Primer se-
quences of Oct3/4 used in these studies are as follows:
forward, 5′-TCTTTCCACC AGGCCCCCGG CTC-3′;
and reverse, 5′-TGCGGGCGGACATGGGGAGATCC-
3′. GAPDH was used as the internal control.
Electrophoresis and western blot analysis
Hearts tissues were homogenized in ice-cold RIPA buffer
(Sigma-Aldrich) containing protease inhibitor cocktails
(Calbiochem, Billerica, MA, USA). Protein lysates were
then obtained after centrifugation at 12,000 × g for 15 mi-
nutes at 4 °C. Protein concentrations were estimated
using a Micro BCA Assay Kit (Thermo Scientific, Rockford,
IL, USA). Proteins (50 μg/lane) were separated on redu-
cing SDS polyacrylamide gels and transferred to PVDF
membranes. Then 5 % nonfat dry milk was used to block
the membranes at room temperature for 1 hour followed
by overnight incubation with primary antibodies at 4 °C.
The membranes were then incubated in the appropriate
horseradish peroxidase-conjugated secondary antibody so-
lution. The blots were incubated with their respective
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polyclonal antibodies Oct3/4 (Santa Cruz Biotech) and β-
actin (1:1000) for 2 hours and visualized by incubation
with anti-rabbit horseradish peroxidase-conjugated sec-
ondary antibody (1:5000) for 1 hour and developed with
ECL Chemiluminescence detection reagent (Amersham
Pharmacia Biotech (Amersham, Buckinghamshire, UK).
Statistical analysis
Data presented in this study are expressed as mean ±
standard error of the mean (SEM). Statistical analysis was
performed with one-way analysis of variance followed by a
Bonferroni correction for multiple comparisons. p <0.05 is
considered statistically significant.
Results
Oct3/4 inhibition prevented c-kit+ CSC transplantation
from restoring LV function post MI
The concentration of Oct3/4 protein and mRNA of
CSCs were determined for cell engraftments into MI
heart. Knockdown of Oct3/4 significantly reduced Oct3/
4 protein and mRNA in CSCs transfected with Oct3/4
siRNA compared with the control siRNA-treated group
(Fig. 1). To investigate whether the preservation of LV
function by c-kit+ CSC transplantation involves Oct3/4,
echocardiographic measurements were performed 2 weeks
after engraftment. As shown in Fig. 2, an increase in left
ventricular internal dimension (LVID) and a significant de-
crease in contractility were observed in MI-PBS groups as
compared with sham-operated mice, indicating a MI-
induced LV dysfunction and myocardial remodeling. Both
LVID;d and LVID;s were depressed in mice receiving control
siRNA-treated CSCs as compared with mice receiving PBS
injection post MI (Fig. 2a, b, e), suggesting that CSC engraft-
ment prevented left ventricular dilation in the MI heart, but
the LV diameters were not reduced in mice receiving Oct3/
4 siRNA-treated CSC injections. Successful engraftment of
CSCs prevented systolic dysfunction in MI mice as evi-
denced by the decreases in ejection fraction and fraction
shortening 2 weeks after surgery as compared with the PBS-
treated MI group, but in mice that received Oct3/4 siRNA-
treated CSCs there was no significant difference observed in
LVEF and LVFS as compared with MI-PBS mice (Fig. 2c, d),
indicating that Oct3/4-deficient CSCs failed to preserve LV
contractility post MI. These results suggest that CSC trans-
plantation restores LV function in the post-MI heart through
an Oct3/4-dependent mechanism.
Inhibition of Oct3/4 suppressed CSC proliferation and
cardiac commitments in post-MI myocardium
GFP served as a marker to identify the CSC progeny in cell-
CSC engrafted myocardium, and Ki67 was utilized to deter-
mine dividing amplifying cells. Mitosis was visualized by PH3,
and EdU staining was also carried out to evaluate cardiomyo-
cyte proliferation. The signals for Ki67, PH3, and EdU in the
sham group demonstrated rare staining, which is shown in
Additional file 1: Figure S1. CSC-derived cardiomyocytes were
identified by GFP and α-actinin double-positive staining was
located in the infarct sites of CSC-engrafted MI hearts as
shown in Fig. 3a, b, but newly formed myocytes were reduced
in MI hearts that received Oct3/4 siRNA-treated CSCs. Myo-
cytes in the sham and control MI groups are shown in Add-
itional file 2: Figure S2. Both Ki67-positive and PH3-postive
myocytes were augmented in the MI myocardium receiving
CSC injections as compared with MI alone, but inhibition of
Oct3/4 resulted in reduced CSC-derived Ki67-positive and
PH3-positive myocytes as shown in Fig. 3c, d, e, f, g, h. EdU-
positive myocytes increased in the MI hearts transplanted
with CSCs as compared with MI alone. However, MI hearts
Fig. 1 Effect of Oct3/4 siRNA transfection on Oct3/4 expression in c-kit+ CSCs. a Densitometric analysis showing Oct3/4 protein in cultured CSCs trans-
fected with control siRNA and Oct3/4 siRNA, respectively. b Western blot showing the representative gel of Oct 3/4 protein. c Real-time PCR showing
Oct3/4 mRNA in cultured c-kit+ CSCs transfected with control siRNA and Oct3/4 siRNA, respectively (n = 3 per group). Values represent mean ± SEM. *p
<0.05 vs. control siRNA. siRNA small interfering RNA
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engrafted with Oct3/4 siRNA-treated CSCs (Fig. 3i, j, k) atten-
uated the EdU-positive myocytes, indicating that Oct3/4 plays
a pivotal role in CSC-driven cardiomyocyte proliferation.
Additionally, there were no differences in cell MEF2C, Ki67,
and PH3-positive cells (data not shown), indicating that the
short-term knockdown of Oct3/4 could not induce a signifi-
cant change in cell proliferation nor differentiation. Likewise,
there was no significant change in cell phenotype.
Inhibition of Oct3/4 abrogated c-kit+ CSC-derived
myocardium regeneration and angiogenesis
To assess the angiogenic responses in post-MI hearts,
we measured the vascular density by immunofluorescent
staining of vascular α-SMA and the capillary density
using CD31 staining which identifies endothelial cells.
Newly formed microvessels were determined with GFP/
α-SMA staining, while GFP/CD31 staining was utilized
Fig. 2 Oct3/4 is required for c-kit+ CSC transplantation to improve impaired LV function in post-MI mice. Echocardiographic measurements of LV
functional parameters: left ventricular internal dimension in diastole (LVID;d) (a), left ventricular internal dimension in systole (LVID;s) (b), ejection
fraction (EF) (c), and fractional shortening (FS) (d). Representative M-mode images (e). Data shown as mean ± SEM (n = 5 per group). ***p <0.001
vs. sham, **p <0.01 vs. sham, #p <0.05 vs. MI + CSCs-Oct3/4 (+) control siRNA, ##p <0.01 vs. MI + CSCs-Oct3/4(+) control siRNA. CSC cardiac stem
cell, MI myocardial infarction, PBS phosphate-buffered saline, siRNA small interfering RNA
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to identify CSC-derived myocardial capillaries. As shown
in Fig. 4a, c, inhibition of Oct3/4 resulted in a substan-
tial reduction in the capillary density in the border area
of CSC-engrafted infarct heart as compared with MI
heart receiving Oct3/4(+) CSCs. α-SMA/GFP staining
demonstrated a decrease in CSC-derived microvessels in
MI hearts engrafted with Oct3/4 siRNA-treated CSCs
(Fig. 4b, d). Both CD31-positive and α-SMA-positive
stainings were detectable in sham and MI hearts as
shown in Additional file 3: Figure S3. In addition, inhib-
ition of Oct3/4 of CSCs showed a slight increase in
apoptotic CSCs in cell-engrafted MI hearts (Additional
file 4: Figure S4). Taken together, the data indicate that
inhibition of Oct3/4 attenuated CSC-promoted cardiac
regeneration and angiogenesis.
Oct3/4 inhibition attenuated the anti-remodeling effect of
c-kit+ CSC transplantation in post-MI heart
Masson’s trichrome staining was used to access morpho-
metric changes in the post-MI heart. As shown in Fig. 5a,
staining images of MI hearts engrafted with Oct3/4(+)
CSCs demonstrated a more viable myocardium with
smaller scar size, indicating that CSC transplantation
can successfully prevent post-MI cardiac remodeling.
Suppression of Oct3/4 of CSCs failed to prevent the MI-
induced remodeling (Fig. 5b). WGA staining was
Fig. 3 Knockdown of Oct3/4 of CSCs inhibited CSC-derived myocyte proliferation and cardiac commitments in post-MI myocardium. a Representative
staining images of c-kit+ CSC-derived cardiomyocytes. c-kit+ CSCs were stained with GFP (red); cardiomyocytes were identified with α-actin (green).
b Quantitative analysis of GFP/α-actin positive myocytes. c, f, i Representative staining images of Ki67/α-actin (c), PH3/α-actin (f), and EdU/α-Actin (i).
Cardiomyocytes were identified with α-actin (green). Ki67 (red), PH3 (red), and EdU (red) were used to determine myocyte proliferation. d, e, g, h, j, k
Quantitative analyses of Ki67, PH3, and EdU staining. The number of positive-stained myocytes was counted in five or six randomly chosen fields per
heart. Three to five hearts were analyzed per group. Data shown as mean ± SEM. *p <0.05 vs. MI-PBS, **p <0.01 vs. MI-PBS, #p <0.05 vs. MI + CSCs-
Oct3/4(+) control siRNA, ##p <0.01 vs. MI + CSCs-Oct3/4(+) control siRNA. Scale bar: 100 μm. CSC cardiac stem cell, DAPI 4,6-diamidino-2-phenylindole,
EdU 5-ethynyl-2′-deoxyuridine, GFP green fluorescent protein, MI myocardial infarction, PBS phosphate-buffered saline, PH3 phosphorylated histone 3,
siRNA small interfering RNA
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performed to measure the size of cardiomyocytes close
to the infarct border. As shown in Fig. 5c, d, MI led to a
significant increase in cross-sectional cardiomyocyte di-
ameters in PBS-treated mice as compared with mice in
the sham group. Oct3/4(+) CSC transplantation led to a
significant reduction in cross-sectional cardiomyocyte
diameters compared with MI-PBS mice, but inhibition
of Oct3/4 abrogated the beneficial effect of CSC treat-
ment of MI heart, suggesting that the anti-remodeling
process of CSC treatment in post-MI heart involves
Oct3/4.
Inhibition of Oct3/4 increased apoptosis and fibrosis in
c-kit+ CSC-engrafted MI heart
TUNEL assay was carried out to determine apoptotic
myocytes in post-MI heart. A significant reduction in
TUNEL-positive myocytes was observed in the infarct
sites of the Oct3/4(+) CSC-engrafted myocardium, but
the anti-apoptotic effect of CSC transplantation was par-
tially attenuated by Oct3/4 suppression as shown in
Fig. 6a, b. Interstitial collagen deposition accompanied
by MI in the mouse heart was evaluated with picro-
sirius red staining. The collagen content was significantly
increased after MI in mice receiving PBS injection as
compared with the sham-operated group (Fig. 6c). Oct3/
4(+) CSC transplantation resulted in a decrease of inter-
stitial collagen in response to MI, which was abolished
in hearts receiving Oct3/4 siRNA-treated CSCs, as the
collagen content remained significantly elevated in those
groups (Fig. 6d), indicating that the prevention of post-
MI apoptosis and fibrosis by CSC transplantation is
dependent on the participation of Oct3/4.
Discussion
Recent developments in stem cell research provide new
approaches in treating MI-induced heart failure focusing
on replacing the damaged myocardium with viable cardi-
omyocytes. Cardiac progenitor cells are shown to have
beneficial effects in preventing negative remodeling pro-
cesses and restoring cardiac function in post-MI hearts
[21, 22]. However, the molecular mechanism(s) by which
CSCs exert myogenesis and cardiac regeneration still
need to be elucidated. Genetic interventions are widely
applied to induce knockdown of specific genes in pro-
genitor cells [23]. In this present study, we observed that
knocking down the Oct3/4 gene using a siRNA transfec-
tion assay abolished beneficial effects of c-kit+ CSC en-
graftment in post-MI mouse heart.
The level of Oct-3/4 expression in ESCs is crucial in
order to maintain their stem cell characteristics, includ-
ing pluripotency. Oct3/4 acts in a gene dose-dependent
manner as a transcriptional organizer in a complex net-
work of tissue specific transcriptional factors in the earl-
ier stages of stem cell and blastocyst differentiation [13].
Fig. 4 Inhibition of Oct3/4 mitigated CSC-derived myocardium
regeneration and angiogenesis in post-MI heart. Representative
images of CD31 (a) and α-SMA (b) staining in post-MI hearts, respectively.
c, d Quantitative analysis of c-kit+ CSC-derived angiogenetic response.
Results were indicated by the number of CD31-positive or α-SMA-
positive cells per mm2. Values shown as mean ± SEM (n = 4 per group);
#p <0.05 vs. MI + CSCs-Oct3/4(+) control siRNA, ##p <0.01 vs. MI +
CSCs-Oct3/4(+) control siRNA. Scale bar: 100 μm. CSC cardiac stem cell,
DAPI 4,6-diamidino-2-phenylindole, GFP green fluorescent protein, MI
myocardial infarction, siRNA small interfering RNA
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A recent observation uncovered key roles of Oct-3/4 in
ESC specification towards a cardiac lineage and in meso-
dermal commitment of the embryonic epiblast [24]. cDNA
antisense-mediated and siRNA-mediated inhibition of up-
regulation of Oct-3/4 in ESCs prevents their specification
towards the mesoderm and their differentiation into cardi-
omyocytes. Furthermore, Oct-3/4 siRNA injected into the
inner cell mass of blastocysts impairs cardiogenesis in early
embryos [25]. In our study, specific inhibition of Oct3/4 in
CSCs resulted in the reduction of cardiac functional im-
provements as compared with control siRNA, which sug-
gests the essential role of Oct3/4 in CSCs to affect c-kit+
CSC-derived myocardial regeneration and functional res-
toration. In addition, hearts in the Oct3/4 siRNA CSC-
treated group demonstrated much greater amounts of ac-
celerated cardiac remodeling and functional dysfunction.
The mechanism is not clear but may be related to the dur-
ation of MI. In agreement with our observations, the previ-
ous study demonstrates that valproic acid, an HDAC
inhibitor, enhances the ability of miniature pig somatic cell
nuclear transfer embryos to develop into blastocysts and
maintains their ability to express the Oct3/4 gene [26].
This is supported by reports [18, 24] which concludes that
Oct3/4, in association with Sox2 and Sox17, works as a key
switch in determining the cardiogenic fate of stem cells. In-
farcted hearts receiving Oct3/4 siRNA-treated CSCs did
not demonstrate a formation of tumorigenesis 6 months
after cell engraftment (data not shown), suggesting that
Oct3/4 inhibition in c-kit+ CSCs does not increase the risk
of developing teratomas. It was reported that the turning
on of the Sox17 promoter will initiate a powerful process
to generate a subset of endoderm-expressing Sox17 to
regulate paracrine signals for cardiogenesis, including a
release of BMP2 into the environment [18] to induce
cardiac specification [27]. It is not clear whether Oct3/4
also directly mediates cardiac transcriptional factors to
direct the fate of cell specification.
Post MI, the left ventricle undergoes a series of architec-
tural and structural changes along with accelerated fibrosis
and collagen deposition, consequently leading to contractile
dysfunction and ultimately heart failure [28, 29]. We and
others have reported previously that engraftment of stem
cells significantly preserved LV function and prevented car-
diac remodeling in the murine heart following LAD
ligation-induced MI [20, 21, 30, 31]. In this study, we dem-
onstrated the anti-remodeling effect of CSC engraftments in
which LV hypertrophic changes featuring enlargement of
LV chambers, increased LV weight, and increased individual
Fig. 5 Inhibition of Oct3/4 attenuated the capacity of CSCs to prevent MI-induced cardiac hypertrophy and remodeling. a Representative images
of Masson’s trichrome-stained myocardial left ventricle in MI hearts receiving c-kit+ CSC transplantation and PBS injection. Scale bar: 100 μm. b
Quantitative analysis of myocardium infarct size. c Representative images of WGA staining in post-MI mouse hearts. Scale bar: 100 μm. d Quantitative
analysis of myocyte cross-sectional area. Data shown as mean ± SEM (n = 3–5 per group). &p <0.05 vs. sham, *p <0.05 vs. MI-PBS, #p <0.05
vs. MI + CSCs-Oct3/4(+) control siRNA. CSC cardiac stem cell, LV left ventricular, MI myocardial infarction, PBS phosphate-buffered saline,
siRNA small interfering RNA
Zhao et al. Stem Cell Research & Therapy  (2015) 6:259 Page 9 of 12
myocyte size were partially prevented by injection of CSCs
into MI myocardium. Post-MI hearts injected with Oct3/4
siRNA-treated CSCs did not show the beneficial effects of
CSCs as they demonstrated the hypertrophic response and
cardiac remodeling. The mechanisms of Oct3/4 of CSCs for
the suppression of cardiac remodeling are not clear. Consid-
ering that attenuation of cardiac remodeling was not attrib-
utable to survival in the myocardium, it is likely that
paracrine effects of CSCs following inhibition of Oct3/4 may
play a role in the event [32]. It is also interesting to study
whether the differences in engrafted cell numbers also im-
pact the magnitude of cardiac remodeling, which could pro-
vide interesting information.
Neovascularization was significantly increased in MI
hearts receiving c-kit+ CSCs, but the enhanced angio-
genesis and atherogenesis were specifically inhibited in
Oct3/4 siRNA-treated CSCs, suggesting that Oct3/4-me-
diated inhibition in microvessels in CSC-engrafted hearts
might also be responsible for the improvement of myo-
cardial function and the reduction of myocardial remod-
eling. This is supported by observations that the
augmentation of neovascularizations in MI hearts was
closely associated with the prevention of cardiac remod-
eling [33, 34]. In this study, the knockdown of Oct3/4 of
c-kit+ CSCs exhibited a decrease in newly formed myo-
cytes in CSC-engrafted MI hearts. Post-MI remodeling
is attributed partially to accelerated fibrosis to an extent
in the right ventricular and LV myocardium caused by
excess pathological collagen deposition [35]. In this
present study we demonstrated that the genetic knock-
ing down of Oct3/4 in c-kit+ CSCs eliminated the anti-
fibrotic effect of CSC transplantation in the post-MI
heart. This is supported by both our and other previous
reports showing that CSCs reduced the post-MI fibrotic
process and reduced infract size [21, 30, 31, 36], suggest-
ing that the anti-remodeling effect of CSCs in cell-
engrafted MI hearts is also mediated through a Oct3/4-
dependent cellular mechanism. The increase in survival
of myocytes in stem cell-engrafted MI hearts has been
extensively observed in experimental in vivo animal
models. Notably, our finding demonstrates that injection
of CSCs reduced apoptotic myocytes in MI heart, but in-
hibition of Oct3/4 abrogated the effect of transplanted
CSCs on reducing myocyte apoptosis. Since the apop-
totic cardiomyocytes within infarcted and remote areas
were detected in this observation, it is likely that both
surviving and newly formed cardiomyocytes could be
subjected to apoptosis during an ischemic environment.
We have demonstrated previously that engrafted CSCs
decreased gradually following engraftment as a result of
the hypoxic environment of MI. Although the function
of Oct3/4 of CSCs is most contributable for modulating
Fig. 6 Inhibition of Oct3/4 attenuated the anti-apoptotic and anti-fibrotic effects of engrafted CSCs in post-MI heart. a Representative images of
TUNEL staining (green, TUNEL-positive staining; red, α-actin; blue, DAPI). Scale bar: 100 μm. b Quantitative analysis of TUNEL-positive nuclei. c
Representative images of picro-sirius red staining. Scale bar: 50 μm. d Quantitative analysis of interstitial collagen deposition in post-MI hearts. Values
shown as mean ± SEM (n = 3–5 per group); &p <0.05 vs. Sham, *p <0.05 vs. MI-PBS, **p <0.01 vs. MI-PBS, #p <0.05 vs. MI + CSCs-Oct3/4(+) control siRNA.
CSC cardiac stem cell, DAPI 4,6-diamidino-2-phenylindole, MI myocardial infarction, PBS phosphate-buffered saline, siRNA small interfering RNA, TUNEL
terminal deoxynucleotidyltransferase nick-end labeling
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cell proliferation and differentiation, we also found that
inhibition of Oct3/4 resulted in a slight increase in apop-
totic signals in cell-engrafted MI hearts. Nevertheless, it
is not clear whether the cardiomyocyte survival rate is
also modulated by Oct3/4, which is limited in this study
and merits further investigation into the effects of Oct3/
4 on stem cells. Furthermore, we did not specifically esti-
mate the time course of cell survival following cell engraft-
ment. Some of the engrafted cells decreased because of
cell death in the hypoxic myocardium, while other
engrafted cells underwent cell differentiation. It would be
interesting to estimate cell death and survival using the
time course of cell engraftment in infarcted heart, which
merits further investigation.
Conclusions
Taken together, our results indicate that transplantation of
cardiac progenitors promoted functional restoration, atten-
uated cardiac hypertrophy, and suppressed remodeling in
CSC-engrafted MI hearts. However, these protective effects
of CSCs on functional improvement and anti-hypertrophic
response in the MI heart were diminished by knockdown
of Oct3/4 of CSCs. Inhibition of Oct3/4 of CSCs mitigated
the CSC-derived cardiac lineage commitment and prolifer-
ation following reintroduction into the MI heart. Further-
more, the increased neovascularization in CSC-engrafted
MI myocardium was also attenuated by knockdown of
Oct3/4 of CSCs. CSC transplantation in the post-MI heart
demonstrated an anti-apoptotic effect in MI hearts, which
was also inhibited by knockdown of Oct3/4 of CSCs. Our
results demonstrate that Oct3/4 plays a crucial role in me-
diating CSCs to induce cardiac regeneration. Our study
not only provides new insights into our understanding of
myocardial repair, but also holds promise in developing a
novel therapeutic approach for cardiac regeneration.
Additional files
Additional file 1: Figure S1. Showing immunostaining signals for Ki67,
phosphorylated histone-3 and EdU from sham myocardium. Representative
immunostaining images from sham hearts. α-Actin (green) was used to stain
cardiomyocytes. Ki67 (red), PH3 (red), and EDU (red) were used to examine
myocyte proliferation. (Staining results from other groups are presented in
Fig. 3f–k.) Scale bar: 100 μm. The detailed procedure is described in Materials
and methods. (TIF 365 kb)
Additional file 2: Figure S2. Showing negative controls for GFP signals
from Sham and MI myocardium. Representative negative control
immunostaining images of c-kit+ CSC-derived cardiomyocytes. GFP
(red) was used to identify c-kit+ CSCs, and cardiomyocytes were
stained with α-actin (green). Only images from sham and MI-PBS
groups are presented. Scale bar: 100 μm. The detailed procedure is
described in Materials and methods. (TIF 350 kb)
Additional file 3: Figure S3. Showing immunostaining signals for CD31
and α-SMA from sham and MI myocardium. Hearts from sham and MI +
PBS groups were stained with CD31 (red) and GFP (green) to determine the
development of c-kit+ CSC-derived capillaries. c-kit+ CSC-derived
vascular smooth muscle cells were stained with α-SMA (green) and GFP
(red). (Positive staining of c-kit+ CSCs from other groups are presented in
Fig. 4a, b) Scale bar: 100 μm. The detailed procedure is described in
Materials and Methods. (TIF 295 kb)
Additional file 4: Figure S4. Showing apoptotic signals from
CSC-engrafted myocardium. A Representative immunostaining images of
apoptosis in post-MI myocardium. Cardiomyocytes that underwent apoptosis
were identified by active caspase-3 (green). CSC-derived cardiomyocytes were
stained with GFP (red). DAPI was used to visualize nuclei. Scale bar: 50 μm. B
GFP-positive apoptotic cells in MI heart that received CSC engraftment.
The unit was normalized to the cell number per mm2. The primary
antibodies that were used in this study include the following: engrafted
CSCs were identified with mouse monoclonal GFP (Clontech, Mountain
View, CA, USA) and costained with polyclonal active caspase 3 (1:100;
Abcam, Cambridge, MA, USA). The methodology for immunostaining is
identical to the described description in Materials and methods. Value
represent mean ± SE (n = 3 hearts per group). (ZIP 271 kb)
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